glp 1 weight loss fda approved A big win for Wegovy: drug semaglutide first in history to gain approval for reducing heart risks The FDA approved a new

Common problems include: Incomplete paperwork: missing fields, unsigned forms, or omitted chart attachments Weak evidence of medical necessity: the diagnosis is present, but the supporting history is thin Missing comorbidity documentation: the condition may be in the patients history but not clearly included in the submission No proof of prior lifestyle effort: many plans want evidence, not just a statement Step therapy gaps: if the plan requires trying another option first, that requirement has to be addressed directly Some patients also run into a coverage issue that has nothing to do with their health

There were no other significant differences (Fig

Kuntz JL, Young DR, Saelens BE, et al

[DOI] [PubMed] [Google Scholar] 187.Amiri S

Note: our weight loss guarantee only applies to patients who start in-office